Currently, clinical trials of anti-CD30 chimeric antigen receptor (CAR30) T-cell therapy are actively conducted in r/r cHL and ALCL, with an overall response rate (ORR) of 53.0–78.0% and a limited median progression-free survival (PFS) of approximately 6.0 months [5–7], indicating the need for novel strategies to further improve its long-term disease control. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.